Treace John T. - 28 Dec 2021 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Lisa Taylor as Attorney-in-fact for John T. Treace
Issuer symbol
TMCI
Transactions as of
28 Dec 2021
Net transactions value
-$388,118
Form type
4
Filing time
30 Dec 2021, 17:01:28 UTC
Previous filing
27 Dec 2021
Next filing
10 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale $335,803 -19,760 -0.36% $16.99 5,425,655 28 Dec 2021 Direct F1, F2
transaction TMCI Common Stock Sale $52,315 -3,075 -0.06% $17.01 5,422,580 29 Dec 2021 Direct F1, F3
holding TMCI Common Stock 1,605,000 28 Dec 2021 By Wife F4
holding TMCI Common Stock 1,471,250 28 Dec 2021 By Wife as cotrustee of the JTT Irrevocable Trust dated September 30, 2020 F4
holding TMCI Common Stock 1,839,063 28 Dec 2021 As Trustee of the Tracy W. Treace Irrevocable Trust dated September 25, 2020 F5
holding TMCI Common Stock 408,816 28 Dec 2021 As Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021 F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.585 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.00 to $ $17.06 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.
F5 The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as Trustee or Co-Trustee.